124584-08-3
Chemical Structure
Nesiritide
Synonym(s): Brain Natriuretic Peptide-32 human; BNP-32
- CAS No.: 124584-08-3
- Formula:C143H244N50O42S4
- Molecular Weight:3464.04
SMILES: O=C(N[C@H](C(NCC(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@@](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(NCC(N[C@H](C(NCC(N[C@@H](CSSC1)C(N[C@@H](CCCCN)C(N[C@@H](C(C)C)C(N[C@@H](CC(C)C)C(N[C@@H](CCCNC(N)=N)C(N[C@@H](CCCNC(N)=N)C(N[C@H](C(O)=O)CC2=CN=CN2)=O)=O)=O)=O)=O)=O)=O)=O)CC(C)C)=O)=O)CO)=O)CO)=O)CO)=O)CO)=O)([H])[C@@H](C)CC)=O)CCCNC(N)=N)=O)CC(O)=O)=O)CCSC)=O)CCCCN)=O)CCCNC(N)=N)=O)=O)CC3=CC=CC=C3)[C@H]1NC(CNC([C@H](CO)NC(CNC([C@H](CCC(N)=O)NC([C@H](C(C)C)NC([C@H](CCSC)NC([C@H](CCCCN)NC([C@H]4N(CCC4)C([C@@H](N)CO)=O)=O)=O)=O)=O)=O)=O)=O)=O
Biological Activity: Nesiritide (Brain Natriuretic Peptide-32 human) is a recombinant human B-type natriuretic peptide. Nesiritide is a NPRs agonist, with Kd values of 7.3 and 13 pM for NPR-A and NPR-C, respectively. Nesiritide regulates V1/2 activation/inactivation of the L-type calcium channel. Nesiritide shows vasodilatory, diuretic, and natriuretic activities. Nesiritide is used in cardiovascular diseases such as heart failure and vascular remodeling after arterial injury[1][2][3][4][5][6][7].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Nesiritide | 99.75% | Nesiritide (Brain Natriuretic Peptide-32 human) is a recombinant human B-type natriuretic peptide. Nesiritide is a NPRs agonist, with Kd values of 7.3 and 13 pM for NPR-A and NPR-C, respectively. Nesiritide regulates V1/2 activation/inactivation of the L-type calcium channel. Nesiritide shows vasodilatory, diuretic, and natriuretic activities. Nesiritide is used in cardiovascular diseases such as heart failure and vascular remodeling after arterial injury. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Sodi R, et al. B-type natriuretic peptide (BNP) attenuates the L-type calcium current and regulates ventricular myocyte function. Regul Pept. 2008 Nov 29;151(1-3):95-105. [Content Brief]
- [2]. Lazar HL, et al. Nesiritide enhances myocardial protection during the revascularization of acutely ischemic myocardium. J Card Surg. 2009 Sep-Oct;24(5):600-5. [Content Brief]
- [3]. Liu S Q, et al. Nesiritide protects endothelial function after balloon-induced trauma in the iliac artery in rabbits. Brazilian Journal of Pharmaceutical Sciences, 2020, 56: e18430.
- [4]. Liu SQ, et al. Treatment with nesiritide, a recombinant B-type natriuretic Peptide, reduces vascular remodeling following balloon-induced endothelial injuries in rabbits. Tohoku J Exp Med. 2010 Nov;222(3):219-23. [Content Brief]
- [5]. Liu SQ, et al. Recombinant B-type natriuretic peptide nesiritide attenuates vascular remodelling by reducing plasma aldosterone in rabbits. Heart Lung Circ. 2012 Sep;21(9):551-5. [Content Brief]
- [6]. Hobbs RE, et al. Therapeutic potential of nesiritide (recombinant b-type natriuretic peptide) in the treatment of heart failure. Expert Opin Investig Drugs. 1999 Jul;8(7):1063-72. [Content Brief]
- [7]. Koller KJ, et al. Molecular biology of the natriuretic peptides and their receptors. Circulation. 1992 Oct;86(4):1081-8. [Content Brief]
Keywords
